Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2017 Aug 22;15(1):68.
doi: 10.1186/s12969-017-0196-7.

Growth and weight gain in children with juvenile idiopathic arthritis: results from the ReACCh-Out cohort

Affiliations
Multicenter Study

Growth and weight gain in children with juvenile idiopathic arthritis: results from the ReACCh-Out cohort

Jaime Guzman et al. Pediatr Rheumatol Online J. .

Abstract

Background: With modern treatments, the effect of juvenile idiopathic arthritis (JIA) on growth may be less than previously reported. Our objective was to describe height, weight and body mass index (BMI) development in a contemporary JIA inception cohort.

Methods: Canadian children newly-diagnosed with JIA 2005-2010 had weight and height measurements every 6 months for 2 years, then yearly up to 5 years. These measurements were used to calculate mean age- and sex-standardized Z-scores, and estimate prevalence and cumulative incidence of growth impairments, and the impact of disease activity and corticosteroids on growth.

Results: One thousand one hundred forty seven children were followed for median 35.5 months. Mean Z-scores, and the point prevalence of short stature (height < 2.5th percentile, 2.5% to 3.4%) and obesity (BMI > 95th percentile, 15.8% to 16.4%) remained unchanged in the whole cohort. Thirty-three children (2.9%) developed new-onset short stature, while 27 (2.4%) developed tall stature (>97.5th percentile). Children with systemic arthritis (n = 77) had an estimated 3-year cumulative incidence of 9.3% (95%CI: 4.3-19.7) for new-onset short stature and 34.4% (23-49.4) for obesity. Most children (81.7%) received no systemic corticosteroids, but 1 mg/Kg/day prednisone-equivalent maintained for 6 months corresponded to a drop of 0.64 height Z-scores (0.56-0.82) and an increase of 0.74 BMI Z-scores (0.56-0.92). An increase of 1 in the 10-cm physician global assessment of disease activity maintained for 6 months corresponded to a drop of 0.01 height Z-scores (0-0.02).

Conclusions: Most children in this modern JIA cohort grew and gained weight as children in the general population. About 1 in 10 children who had systemic arthritis, uncontrolled disease and/or prolonged corticosteroid use, had increased risk of growth impairment.

Keywords: Corticosteroids; Growth; Juvenile arthritis; Obesity.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

The study was approved by research ethics boards at each participating institution. Parents provided informed written consent, and patients provided assent where appropriate.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Subject eligibility and disposition
Fig. 2
Fig. 2
Smoothed trajectories of mean Z-scores. Shown are trajectories of (a) height, (b) weight, and (c) BMI for each JIA category in the 3 years after diagnosis. Panel (d) shows Z-score trajectories for the whole cohort. Trajectories of the mean Z-score were charted using locally weighted scatter plot smoothing with a band width of 0.6. The black dashed horizontal line represents healthy growth standards
Fig. 3
Fig. 3
Point prevalence of short stature and obesity in the whole cohort. Shown are the point prevalences of a) short stature and b) obesity in the whole cohort at every study visits for the 3 years after enrolment, and after excluding children who received corticosteroids. The vertical lines represent 95%CI

References

    1. Harrold LR, Salman C, Shoor S, Curtis JR, Asgari MM, Gelfand GM, et al. Incidence and prevalence of juvenile idiopathic arthritis among children in a managed care population, 1996-2009. J Rheumatol. 2013;40(7):1218–1225. doi: 10.3899/jrheum.120661. - DOI - PMC - PubMed
    1. Petty RE, Southwood TR, Manners P, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol2004;31(2):390–2. - PubMed
    1. Guzman J, Oen K, Tucker LB, Huber AM, Shiff N, Boire G, Scuccimarri R, Berard R, Tse SM, Morishita K, Stringer E, Johnson N, Levy DM, Duffy KW, Cabral DA, Rosenberg AM, Larché M, Dancey P, Petty RE, Laxer RM, Silverman E, Miettunen P, Chetaille AL, Haddad E, Houghton K, Spiegel L, Turvey SE, Schmeling H, Lang B, Ellsworth J, Ramsey S, Bruns A, Campillo S, Benseler S, Chédeville G, Schneider R, Yeung R, Duffy CM, for the ReACCh-Out investigators The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort. Ann Rheum Dis. 2015;74(10):1854–1860. doi: 10.1136/annrheumdis-2014-205372. - DOI - PubMed
    1. Simon D. Inflammation and growth. J Pediatr Gastroenterol Nutr. 2010;51(Suppl3):S133–S134. doi: 10.1097/MPG.0b013e3181f7feef. - DOI - PubMed
    1. Bechtold S, Simon D. Growth abnormalities in children and adolescents with juvenile idiopathic arthritis. Rheumatol Int. 2014;34(11):1483–1488. doi: 10.1007/s00296-014-3022-2. - DOI - PubMed

Publication types

Substances